Edgewise Therapeutics, Inc. (EWTX), a muscle disease biopharmaceutical, has several key catalysts to watch in the coming days, with pivotal data expected from its trials of Sevasemten and EDG-7500.
Sevasemten is a first-in-class oral drug designed to target fast skeletal myosin, a key component in muscle contraction. It is aimed at protecting unstable muscles from damage caused by contraction in muscular dystrophies like Becker and Duchenne Muscular Dystrophy (DMD).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com